Abstract
In 2010, only about 8% of Medicare Part D enrollees who were eligible for a comprehensive medication review (CMR) received one, according to CMS. Cynthia Tudor, PhD, Director of the Medicare Drug Benefi t and C and D Data Group, predicted last March at the CMS 2012 Medicare Prescription Drug Benefi t Symposium that the number of eligible patients who receive the review will rise as more patients become aware of MTM and its value.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
